Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stanmore appoints Eric Dodd CFO

This article was originally published in Clinica

Executive Summary

UK orthopaedics firm Stanmore Implants has appointed Eric Dodd chief financial officer. Mr Dodd was most recently CFO of European biotech company Antisoma, a position he held for three years. Before this, he was group finance director for Morse, a British IT consultancy group. Mr Dodd has also worked for GlaxoSmithKline and Deloitte & Touche. Elstree-based Stanmore is currently expanding its product offering and entering new markets. In June, the company received US FDA 510(k) clearance for its Juvenile Tumour System (JTS), a noninvasive distal femoral replacement implant that uses an electromagnetic device to lengthen the prosthesis (www.clinica.co.uk, 27 June 2011).

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT097769

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel